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Summary  Nowadays,  antiplatelet  and  anticoagulant  drug  medications  are  indicated  in
patients with  a  variety  of  cardiovascular  disorders,  such  as  atrial  ﬁbrillation,  coronary  artery
disease, and  peripheral  artery  disease.  Among  cardiology  patients,  regardless  of  gastrointestinal
(GI) protection,  we  do  not  infrequently  encounter  those  patients  who  have  signs  and  symptoms
that are  suggestive  of  GI  tract  problems.  We  should  bear  in  mind  that  such  GI  signs  and  symp-
toms may  be  attributed  to  GI  cancers,  as  well  as  to  benign  or  clinically  insigniﬁcant  lesions.
Several clinical  studies  have  shown,  albeit  controversially  that  the  predictive  value  of  posi-
tive fecal  occult  blood  for  colorectal  malignant  neoplasm  may  not  be  lower  in  patients  taking
antithrombotic  medication.  In  addition,  it  has  been  shown  that  in  patients  taking  antithrom-
botic drug(s),  diagnosed  colorectal  malignancies  are  in  a  relatively  earlier  phase,  suggesting
that antithrombotic  drugs  may  facilitate  the  detection  of  otherwise  unrecognized  cancers.  The
possibility  also  exists  that  certain  cardiovascular  disease  may  be  associated  with  a  higher  risk
of GI  malignant  neoplasms.  There  has  been  no  established  evidence  concerning  whether  more
aggressive  GI  tract  screening  will  reduce  the  probability  of  cancer  death  in  cardiology  patients;
nevertheless,  GI  tract  lesions  should  not  be  overlooked  among  cardiology  patients,  especially
when unexplained  anemia,  gastrointestinal  symptoms,  or  positive  fecal  occult  blood  test  is
present, and  GI  tract  screening  should  be  performed  with  appropriate  timing.
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or  ticlopidine)  user  profoundly  reduced  the  risk  of  upper  GI
bleeding  with  a  relative  risk  of  0.19  (95%  CI  0.07—0.49)  [26].References ................................................
ntroduction
vidence  is  accumulating  over  the  beneﬁts  of  both  primary
nd  secondary  treatment  strategies  for  cardiovascular  dis-
ase  [1,2]  and  stroke  [3,4], and  the  use  of  antiplatelet  and
nticoagulant  drugs  continues  to  increase.  On  the  other
and,  as  a  trade-off,  the  need  for  gastrointestinal  (GI)
ract  protection,  mainly  against  bleeding  [5]  is  increasing,
ecause  GI  bleeding  is  one  of  the  most  common  causes  of
dverse  drug  reaction-related  admissions  [6].  In  fact,  Ko
t  al.  recently  reported  that  2.5%  of  patients  were  hospi-
alized  for  bleeding  within  a  year  of  percutaneous  coronary
ntervention,  and  more  than  half  of  these  admissions  were
ue  to  GI  bleeding  [7].  Therefore,  minimization  of  the
uration  of  antithrombotic  drug  use  should  be  considered,
specially  when  dual  or  triple  therapy  is  used.  Although  acid
uppressants  may  effectively  reduce  antithrombotic  drug-
nduced  GI  bleeding  [8],  malignant  neoplasm  in  such  patients
ight  be  overlooked  under  the  simple  presumption  that  pro-
ressive  anemia  and/or  a  positive  fecal  blood  test  (FOBT),
hich  has  high  sensitivity  for  colorectal  neoplasm  [9],  may
e  caused  by  bleeding  from  benign  or  non-signiﬁcant  lesions
ropagated  by  the  antithrombotic  drugs,  leading  to  lack  of
urther  examination,  for  example,  by  GI  endoscopy.  It  should
e  questioned,  however,  whether  antithrombotic  use  will
ncrease  or  decrease  the  positive  predictive  value  of  cancer
creening,  because  bleeding  from  malignant  neoplasm,  as
ell  as  from  non-malignant  lesions,  might  be  facilitated  by
ntiplatelet  and  anticoagulant  drugs.
The  emergence  of  a  new  class  of  antithrombotic  drugs
10,11]  and  gastroprotective  agents  [12], coupled  with  an
ncrease  in  the  use  of  dual  and  triple  therapies,  makes  it
ifﬁcult  and  rather  complex  to  answer  this  question;  in
ddition,  environmental  changes  might  alter  the  risk  of  GI
leeding  from  non-malignant  and  malignant  lesions  [13]. It
as  been  suggested  that  the  prevalence  and/or  discovery  of
alignant  neoplasm  may  show  an  increasing  trend  in  Japan,
onsidering  that  modalities  for  GI  tract  screening,  such  as
ndoscopies  [14]  and  computed  tomography  colonography
15], are  increasingly  available  and  feasible,  and  that  GI
ract  malignancies  may  become  more  prevalent  according
o  the  rapid  aging  of  the  population  [16]; therefore,  car-
iologists  may  have  to  take  the  most  cautious  approach  of
hecking  for  concomitant  GI  tract  malignancies  in  cardiology
atients.  Here,  we  brieﬂy  review  the  prediction  of  cancer  by
ndoscopic  examination  in  subjects  taking  antithrombotic
rugs,  and  the  incidence  of  GI  tract  malignancies  in  patients
ith  cardiovascular  disease.
A
o..........................................................  204
pper gastrointestinal bleeding by
ntithrombotic drugs
ntithrombotic  drug  medication  increases  the  incidence  of
pper  GI  bleeding,  although  the  frequency  of  this  bleed-
ng  may  differ  according  to  the  population  studied  and  to
he  types  of  ulcer  protective  medication  administered  [17].
lthough  antiplatelet  drug  medication  has  been  shown  to
e  effective  in  preventing  myocardial  infarction  [18], GI
leeding  is  still  one  of  the  limiting  factors  for  antiplatelet
se  [19]. In  a  positive  cohort  study  including  32,989  men,
or  example,  Huang  et  al.  showed  that  long-term  regular
spirin  use  increased  the  risk  of  GI  bleeding,  especially
rom  the  upper  GI  [20]. Furthermore,  in  a  case—control
tudy  comparing  patients  who  had  a  history  of  gastric  or
uodenal  bleeding  with  7193  matched  controls,  clopidogrel
ncreased  the  risk  of  upper  GI  bleeding  with  an  odds  ratio
f  2.3  [95%  conﬁdence  interval  (CI)  0.9—6.0]  [21]. Clopi-
ogrel  may  not  induce  gastric  damage  in  healthy  subjects
22];  however,  it  may  increase  the  incidence  of  recurrent
eptic  ulcer  in  patients  with  atherosclerosis  and  a  history  of
eptic  ulcers  [23]. Oral  anticoagulants  may  also  signiﬁcantly
ncrease  the  risk  of  upper  GI  bleeding  with  a  relative  risk
f  1.77  [24].
The  risk  of  upper  GI  bleeding  by  antiplatelet  agents
as  been  shown  to  be  enhanced  when  dual  antiplatelet
rugs  are  used  or  when  anticoagulant  drug  is  concomitantly
sed.  Yusuf  et  al.  showed  that  addition  of  clopidogrel  to
spirin,  which  acts  favorably  in  patients  with  acute  coro-
ary  syndrome,  increased  the  risk  of  major  bleeding,  with
n  increase  in  the  frequency  of  GI  bleeding  from  0.7%  to
.3%  [25]. By  analyzing  the  Health  Improvement  Network  UK
rimary  care  database,  García  Rodríguez  et  al.  found  that
se  of  low-dose  aspirin  increased  2-fold  the  risk  of  upper
I  bleeding  as  compared  with  nonuse,  and  that  the  risk  of
pper  GI  bleeding  was  further  increased  when  clopidogrel
nd  oral  anticoagulants  were  used  concomitantly,  with  a  rel-
tive  risk  of  2.08  and  2.00,  respectively  [24]. In  patients  with
pper  GI  hemorrhage  that  was  conﬁrmed  endoscopically,
anas  et  al.  reported  that  the  use  of  non-aspirin  antiplatelet
gents  increased  upper  GI  bleeding  with  a  relative  risk  of
.2  (95%  CI  2.2—4.4)  [26]. In  that  study,  the  prescription  of
 proton  pump  inhibitor  for  a  thienopyridine  (clopidogrel recent  consensus  statement  from  the  American  College
f  Cardiology  Foundation  task  force  recommended  the  use
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aGastrointestinal  malignancy  in  cardiology  patients  
of  proton  pump  inhibitors  for  the  therapy  and  prophylaxis
of  aspirin-associated  GI  injury  to  prevent  adverse  GI  events
with  antiplatelet  therapy  [27].
The incidence  of  upper  GI  bleeding  from  a  peptic  ulcer  is
increased  by  antithrombotic  drugs;  however,  whether  such
drugs  also  increase  the  risk  of  upper  GI  bleeding  from  malig-
nant  neoplasm  seems  to  have  been  less  extensively  studied.
By  analyzing  the  data  of  patients  who  were  referred  for  eval-
uation  of  a  positive  FOBT  and  who  underwent  colonoscopy
and  same-day  upper  GI  tract  endoscopy,  Bini  et  al.  found
that  there  was  no  difference  in  the  frequency  of  upper  GI
lesions  between  those  who  were  taking  warfarin  and  those
who  were  not,  although  colonic  lesions  were  signiﬁcantly
more  common  in  the  warfarin  group  [28]. Furthermore,  in  a
double-blind,  prospective  study,  Greenberg  et  al.  reported
that  aspirin  did  not  cause  signiﬁcant  gastric  or  duodenal
mucosal  endoscopic  lesions  [29], although  healthy  volun-
teers  were  enrolled  in  the  study.
Colorectal bleeding, positive fecal occult
blood test, and antithrombotic drugs
A  randomized  trial  has  shown  that  screening  for  colorectal
cancer  by  FOBT  and,  if  positive,  by  subsequent  diagnostic
evaluation  using  colonoscopy,  for  example,  reduces  mortal-
ity  from  colon  cancer  [30]. The  American  Cancer  Society,  the
American  Gastroenterological  Association,  and  the  United
States  Preventive  Task  Force  recommend  an  annual  FOBT
to  detect  cancer,  and  ﬂexible  sigmoidscopy,  colonoscopy,
double-contrast  barium  enema,  or  computed  tomographic
colonography  to  detect  adenomatous  polyps  and  cancer  in
subjects  aged  50  years  and  older  with  the  goal  of  cancer
prevention  [31].
It may  therefore  be  questioned  whether  antithrombotic
medication  will  increase  the  need  for  colonoscopic  exami-
nation  by  increasing  FOBT  positivity.  If  antithrombotic  drugs
increase  the  frequency  of  a  positive  FOBT  by  facilitating
hemorrhage  from  cancer  and/or  adenomatous  polyps,  these
drugs  may  beneﬁcially  increase  the  chance  of  detecting
these  life-threatening  neoplasms.  On  the  other  hand,  if
antithrombotic  drugs  increase  the  likelihood  of  hemorrhage
from  non-malignant  colorectal  lesions,  then  antithrombotic
drug  use  may  unfavorably  reduce  the  cost-effectiveness  of
the  FOBT;  if  positive  predictive  value  decreases,  the  ces-
sation  of  antithrombotic  drugs  during  stool  collection  may
have  to  be  considered.
Several  clinical  studies,  although  not  large-scale,  have
been  designed  to  answer  this  question.  In  a  double-blind,
prospective  study,  Greenberg  et  al.  reported  that,  in  the
absence  of  frank  ulceration,  low-dose  aspirin  did  not  result
in  a  positive  FOBT  [29]. In  that  study,  however,  healthy  vol-
unteers  underwent  only  30  days  of  treatment  with  daily
aspirin  or  placebo.  In  a  prospective,  cross-over  study,  in
which  100  participants  over  40  years  of  age  were  enrolled,
the  same  group  reported  that  aspirin,  but  not  warfarin,
caused  a  small  but  clinically  insigniﬁcant  increase  in  occult
fecal  blood;  therefore,  patients  taking  either  low-dose
aspirin  or  warfarin  can  be  managed  in  the  same  fashion  as
patients  not  taking  these  medications  [32]. Again  it  should
be  noted  that,  essentially  healthy  subjects  who  were  not  on
antithrombotic  drugs  on  a  regular  basis  were  enrolled  in  that
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tudy.  The  target  population  property  is  an  important  param-
ter  affecting  the  results  of  such  studies,  because  the  risk
f  anticoagulation-related  bleeding  may  increase  in  older
ubjects  and  in  those  who  are  concomitantly  using  other
ntithrombotic  drugs  [33].
Kahi  and  Imperiale  conducted  a  prospective  cohort  study,
n  which  193  patients  with  a  mean  age  of  66  years  were
eferred  for  colonoscopy  to  evaluate  a  positive  FOBT  result.
atients  on  warfarin  treatment  were  excluded  from  this
tudy.  Among  135  patients  on  regular  aspirin  or  non-steroidal
nti-inﬂammatory  drug  (NSAID)  treatment,  29  (21%)  had
ndings  to  explain  the  positive  test  results,  as  compared
ith  11  (19%)  among  58  non-users,  indicating  that  aspirin
nd  NSAID  use  may  not  increase  the  frequency  false-
ositive  FOBT  results  [34]. This  study’s  results  seem  to  have
ore  clinical  relevance  than  Greenberg’s  study,  because
t  involved  individuals  who  took  aspirin  for  primary  or
econdary  prophylaxis  of  cardiovascular  or  cerebrovascu-
ar  disease.  Nevertheless,  Kahi  et  al.’s  study  was  limited
n  that  right-sided  colitis,  and  vascular  lesions  were  also
onsidered  to  be  lesions  that  would  explain  the  positive
est  results,  although  the  tests  were  primarily  developed
or  the  detection  of  advanced  neoplasia  (cancer,  large
olyps,  or  polyps  ≥10  mm,  or  polyps  with  villous  histol-
gy).
In  a  prospective  study,  Bini  et  al.  investigated  patients
eferred  for  the  evaluation  of  a  positive  FOBT  [28]. Among
10  patients  on  warfarin,  and  210  patients  not  on  war-
arin,  adenoma  was  found  in  39  (18.6%)  and  29  (13.8%),  and
arcinoma  in  18  (8.6%)  and  22  (10.5%),  respectively,  indi-
ating  that  warfarin  treatment  may  not  increase  the  risk  of
etecting  non-neoplastic  lesions  in  FOBT-positive  subjects.
he  frequency  of  GI  lesions  was  greater  in  those  with  a
igher  international  normalized  ratio,  although  the  differ-
nce  was  not  statistically  signiﬁcant.  It  is  of  note  that,  as
ompared  with  patients  who  were  not  taking  oral  anticoagu-
ants,  those  taking  warfarin  showed  an  increased  frequency
f  the  detection  of  ‘early-stage’  colorectal  cancers.  Bini
t  al.  suggested  that  the  earlier  detection  of  colorectal
ancer  in  patients  taking  warfarin  may  be  explained  by
he  unmasking  —  by  anticoagulation  therapy  —  of  bleed-
ng  from  early  stage  lesions  that  otherwise  would  not  have
een  diagnosed  [35,36],  although  this  notion  requires  fur-
her  evaluation.
In  contrast,  Sawhney  et  al.  found  that  use  of  antico-
gulant  and  antiplatelet  medications  lowered  the  positive
redictive  value  of  FOBT  for  advanced  colonic  neoplasia
y  analyzing  the  data  of  patients  who  were  referred  for
olonoscopy  for  a  positive  FOBT  [37]. They  found  that  the
ositive  predictive  value  of  FOBT  for  advanced  colon  neo-
lasia  and  colorectal  cancer,  respectively,  was  30.5%  and
.2%  among  antithrombotic  drug  non-users,  and  20.5%  and
.4%  among  aspirin  users  (Fig.  1).  In  addition,  clopidogrel
ppeared  to  have  a  more  negative  effect  on  the  positive
redictive  value  of  FOBT,  as  compared  with  aspirin  and  war-
arin.
Clarke  et  al.  studied  the  data  of  846  participants  with
 positive  FOBT  who  underwent  colonoscopy,  of  which
01  patients  were  taking  regular  antithrombotic  medica-
ion  (aspirin,  n  =  183;  warfarin,  n  =  26;  others,  n  =  127)  [38].
n  this  study,  47.5%  of  anticoagulant  users  were  found  to
ave  colorectal  neoplasia,  whereas  a  signiﬁcantly  higher
202  N.  Ishizaka  et  al.
Figure  1  Comparison  of  the  positive  predictive  value  of
fecal occult  blood  test  for  advanced  colonic  neoplasia  between
patients  who  were  taking  antithrombotic  drugs  or  non-steroidal
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Figure  2  Prevalence  of  advanced  colorectal  adenoma  accord-
ing to  computed  tomography  angiography  (CTA)  ﬁndings.  The
proportion  of  advanced  colorectal  adenoma  was  higher  in
patients  with  signiﬁcant  coronary  artery  disease  (CAD,  *p  for
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nnti-inﬂammatory  drugs  (NSAIDs)  and  control  subjects.
dapted  from  Sawhney  et  al.  [37].
ercentage  (56.5%)  of  anticoagulant  non-users  were  found
o  have  neoplasia.
Notwithstanding  these  observations  [37,38],  however,
nd  considering  that  the  main  purpose  of  colorectal
creening  is  to  detect  neoplastic  disease,  we  cannot  neglect
he  possibility  of  colorectal  cancers  in  patients  with  a
ositive  FOBT,  even  in  those  taking  antithrombotic  drugs,
ecause  the  extent  of  reduction  in  the  positive  predictive
alue  was,  although  statistically  signiﬁcant,  small.  If  previ-
usly  unrecognized  colorectal  malignancies  can  indeed  be
ore  easily  discovered  by  anticoagulant  [39]  or  antiplatelet
40]  therapy,  we  cannot  neglect  a  positive  FOBT  in  patients
ho  are  taking  antithrombotic  drugs.
oronary heart disease and gastrointestinal
ancers
everal  previous  studies  have  suggested  that  GI  tract  malig-
ancies  are  more  prevalent  in  subjects  with  coronary
rtery  disease  (CAD).  This  information  is  important  because
ntithrombotic  drugs  are  more  frequently  given  to  patients
ith  coronary  heart  disease.  Sawhney  reported  that,  among
hose  patients  who  underwent  colonoscopy,  CAD  was  an
ndependent  predictor  for  advanced  colonic  neoplasia  [37].
Chan  et  al.  reported  that  among  subjects  who  under-
ent  colonoscopy,  colorectal  cancer  was  found  in  19.0%
atients  with  CAD  as  compared  with  7.7%  without.  This
tudy  included  only  data  from  patients  who  had  signs  and
ymptoms  associated  with  the  GI  tract;  namely,  abdominal
ain,  altered  bowel  habit,  iron  deﬁciency  anemia,  con-
tipation,  diarrhea,  inﬂammatory  bowel  disease,  melena,
ositive  fecal  occult  blood,  and  per-rectal  bleeding  [41].
ore  recently,  Chan  et  al.  conducted  a  clinical  study  in
hich  patients  were  recruited  for  screening  colonoscopy
fter  undergoing  coronary  angiography  for  the  ﬁrst  time  for
uspected  CAD.  In  this  study,  advanced  colorectal  lesions,
eﬁned  as  the  presence  of  cancer  or  adenomas  with  a  vil-
ous  component,  high-grade  dysplasia,  or  a  size  of  1  cm  or
arger  were  found  in  18.4%,  8.7%,  and  5.8%,  while  preva-
ence  of  cancer  was  found  in  4.4%,  0.5%,  and  1.4%,  of  the
AD-positive,  CAD-negative,  and  general  population  groups,
espectively  [42]. The  prevalence  of  colorectal  neoplasm
as  higher  in  CAD-positive  patients  than  in  CAD-negative
atients.  It  is  possible  that  the  greater  prevalence  of
C
c
i
rrend =  0.005).
dapted  from  Yang  et  al.  [45].
olorectal  neoplasm  in  CAD-positive  patients  may  be
ttributed  to  the  fact  that  many  risk  factors  are  shared
etween  CAD  and  colorectal  neoplasm,  such  as  advanced
ge,  male  sex,  smoking,  obesity,  and  diabetes  [43]. The
nexpectedly  high  prevalence  of  colorectal  cancer  (4.4%)
nd  advanced  neoplasia  (18.4%)  in  CAD-positive  patients
hich  Chan  et  al.  found  in  this  study,  however,  needs  to
e  conﬁrmed  in  other  studies  [44].
In  an  analysis  of  cross-sectional  data  from  Korean  men
ho  presented  for  a  health  check-up,  Yang  et  al.  recently
eported  that  subjects  with  signiﬁcant  coronary  disease,  as
hown  by  computed  tomography  coronary  angiography,  had
 greater  prevalence  of  advanced  adenoma  [45]  (Fig.  2).
lthough  coronary  artery  lesion  was  not  validated  by  coro-
ary  angiography  in  this  study,  it  is  of  value  that  the  study
ubjects  underwent  colonoscopy  irrespective  of  the  pres-
nce  or  absence  of  fecal  occult  blood.  Notably,  about  20%
f  the  subjects  who  had  signiﬁcant  CAD  had  advanced  ade-
oma,  indicating  the  intense  association  between  coronary
therosclerosis  and  colorectal  adenoma  in  Korean  men.
trial ﬁbrillation and gastrointestinal cancers
everal  previous  studies  have  suggested  that  there  is  a
igher  prevalence  of  GI  cancers  in  patients  with  atrial
brillation.  In  a  case—control  study  with  5—10  years  of
bservation,  Muller  et  al.  reported  that  atrial  ﬁbrilla-
ion  and  ﬂutter  were  associated  with  colon  cancer  with
igher  probability  than  those  without  [46]. Guzzetti  et  al.
eported  in  a  case—control  study  that  prevalence  of  atrial
brillation  was  greater  in  patients  admitted  for  surgical
reatment  of  colorectal  cancer  than  in  those  admitted  for
on-neoplastic  diseases  with  an  odds  ratio  of  3.5  (95%
I  1.6—7.2)  [47]. Warfarin  therapy  can  be  problematic  in
ancer-harboring  patients  because  of  a higher  risk  of  bleed-
ng  [48,49].  Although  the  causal  and  resultant  relationships
emain  clear,  impairment  of  autonomic  function  [50], and
Gastrointestinal  malignancy  in  cardiology  patients  203
Figure  3  Cause  of  death  in  heart  failure  patients  (A)  and  non-cardiovascular  causes  of  death  in  heart  failure  patients  (B).  (For
interpretation  of  the  references  to  color  in  this  artwork,  the  reader  is  referred  to  the  web  version  of  this  article.)
may  be  attributed  to  the  fact  that  heart  failure  and  cancers
share  several  risk  factors  in  common;  these  include  cigarette
smoking,  diabetes,  and  obesity  [55,56];  however,  the  com-
plex  interactions  between  comorbidities  and  outcome  in
heart  failure  patients  have  not  been  fully  established  [57].Adapted from  Pons  et  al.  [53].
abnormalities  in  hormonal  and  immune  systems  [51]  are
suspected  to  be  involved  in  the  underlying  mechanism
linking  atrial  ﬁbrillation  and  cancer.  We  should  be  aware
of  this  association  between  atrial  ﬁbrillation  and  colorec-
tal  cancer  by  checking  for  fecal  occult  bleeding  in  these
patients.
Heart failure and gastrointestinal cancers
Antithrombotic  drugs  may  be  prescribed  for  patients  with
heart  failure  because  of  the  presence  of  atrial  ﬁbrilla-
tion,  CAD,  and  reduced  ejection  fraction,  although  the  role
of  antithrombotic  therapy  in  patients  with  chronic  heart
failure  has  long  been  debated,  and  remains  controversial
[52].  In  parallel  with  an  improvement  in  the  prognosis  of
heart  failure  patients,  noncardiac  causes  are  increasingly
accounting  for  a  substantial  proportion  of  deaths,  especially
among  elderly  heart  failure  patients.  Pons  et  al.  reported
that,  in  a  study  with  a  median  of  follow-up  of  36  months,
among  960  patients  with  New  York  Heart  Association  func-
tional  class  II  or  III,  there  were  351  deaths,  of  which  94
(27%)  were  due  to  noncardiovascular  causes;  in  addition,
39%  of  the  noncardiac  deaths  were  attributed  to  malignan-
cies  [53]  (Fig.  3).  We  may  have  to  become  more  aware  of
the  possibility  of  the  presence  of  undiagnosed  malignan-
cies  to  further  improve  the  prognosis  of  patients  with  heart
failure.
Certain  comorbidities,  including  cancer,  were  found  to  be
associated  with  increased  long-term  mortality  and  hospital-
izations  in  the  heart  failure  patient  [54], and  this  association
Figure  4  Kaplan—Meier  curves  for  death  due  to  cancer  among
controls  (Control  Group)  and  in  patients  with  peripheral  arterial
disease  (PAD  Group).  *Log  rank  test  p  <  =  0.05.
Adapted  from  Fiotti  et  al.  [63].
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eripheral artery disease, abdominal
neurysm,  and gastrointestinal cancers
t  has  been  recognized  that  colorectal  neoplasm  may  occa-
ionally  coexist  with  abdominal  aortic  aneurysm  (AAA),
hich  causes  a  dilemma  for  the  surgeon  because  it  is
ften  difﬁcult  to  decide  whether  to  treat  the  carcinoma
r  the  aneurysm  ﬁrst  [58,59].  Yamamoto  et  al.  reported
hat,  among  408  patients  admitted  for  elective  surgery  of
AA  (248  patients)  or  peripheral  atherosclerotic  disease
PAD;  244  patients)  who  underwent  FOBT,  104  (25.5%)  had  a
ositive  FOBT  and  thus  underwent  further  colorectal  inves-
igation  by  barium  enema,  and  if  lesions  were  found  to  be
resent,  by  subsequent  colonoscopy.  Six  (1.5%)  colorectal
arcinomas  and  16  (3.9%)  advanced  adenomas  were  found
nd  about  one-third  of  positive  FOBT  patients  appeared
o  have  advanced  neoplasm  [60], the  incidences  of  which
eem  to  be  several-fold  higher  than  that  among  the  general
opulation.  The  observed  prevalence  of  advanced  neopla-
ia  was  higher  than  that  reported  in  the  general  population
61,62].
By  following-up  patients  with  PAD  together  with  sex-
nd  age-matched  controls  from  1974  to  1998,  Fiotti  et  al.
ound  that  PAD  patients  had  a  signiﬁcantly  higher  mortal-
ty  rate  than  controls,  and  the  commonest  cause  of  death
as  cancer,  mostly  of  the  lung,  stomach,  and  colon  [63].
n  Fiotti  et  al.’s  study,  a  higher  incidence  of  cancer  of  the
I  tract  was  observed  in  PAD  patients  as  compared  with
ontrol  subjects  (0.40  vs.  0.19,  100  patient-yr,  p  <  0.05)
Fig.  4).  Furthermore,  Komori  et  al.  reported  that  among
22  patients  with  AAA  admitted  between  1985  and  1992,
 patients  (3.2%)  were  found  to  have  concomitant  gastric
ancer  [64]. Although  the  percentages  may  vary  according
o  the  population  studied,  several  studies  have  reported
 lower  incidence  of  concomitant  AAA  and  GI  tract  malig-
ancy.  For  example,  Nora  et  al.  found  that,  among  a  series
f  3500  AAAs  repaired  at  the  Mayo  Clinic  over  a  12-year
eriod,  only  17  (0.7%)  were  associated  with  a  colorectal
alignancy  [65]. Furthermore,  Robinson  et  al.  reported
hat,  among  1337  aneurysms  treated  over  a  10-year  period,
9  (1.4%)  were  associated  with  a  concomitant  colorectal
alignancy  [66]. It  should  be  noted,  however,  that  rou-
ine  FOBT  screening  and  subsequent  colonoscopy  may  not
ave  been  performed  in  this  study.  These  ﬁndings  support
he  notion  that  GI  tract  malignancies  may  be  occasionally
ncountered  with  abdominal  aneurysm,  which  may  make
he  surgical  decision  more  complex  than  if  they  were  absent
64].
Should  we  discontinue  antithrombotic  drugs  before
ndoscopic  examination  to  prevent  a  negative  predictive
alue?
Because  usage  of  antithrombotic  drugs  may  increase  the
egative-prediction  for  colorectal  cancers  in  FOBT-positive
ubjects  [37,38],  some  studies  recommend  the  temporary
essation  of  such  medication,  when  it  does  not  pose  a risk
o  the  patient-from  the  viewpoint  of  cost-effectiveness.
owever,  this  situation  may  differ  according  to  the  coun-
ry  and  health  insurance  system.  Needless  to  say,  whether
ntithrombotic  drugs  should  be  stopped  or  converted  into
eparin  for  the  purpose  of  biopsy  is  another  important  issue
o  be  considered.N.  Ishizaka  et  al.
onclusions
long  with  the  improvement  of  the  prognosis  of  cardiovas-
ular  disorders,  it  is  logically  thought  that  number  of  the
ardiology  patients  who  will  eventually  experience  malig-
ant  disease  will  increase,  considering  cancer  is  one  of
he  aging-associated  diseases.  In  addition,  several  previous
eports  suggested  the  higher  incidence  of  GI  malignancies
n  patients  with  cardiovascular  diseases  [41,67]. There  is
o  ﬁrm  evidence  to  support  the  notion  that  GI  tract  can-
er  is  underdiagnosed  in  cardiology  patients,  and  that  more
ggressive  GI  tract  screening  would  reduce  the  probability
f  cancer-associated  death  in  cardiology  patients.  On  the
ther  hand,  however,  several  previous  reports  showed  that
he  risk  of  GI  tract  cancers  and/or  advanced  neoplasm  might
e  increased  in  patients  with  coronary  heart  disease,  atrial
brillation,  aortic  aneurysm,  and  PAD  [42,47,60].  In  addi-
ion,  a  possibility  has  been  suggested  that  antiplatelet  and
nticoagulant  drug  use  might  lead  to  earlier  discovery  of
I  tract  cancer  by  unmasking  bleeding  from  advanced  neo-
lasms  that  may  be  in  an  early  stage  [35,36,40]. GI  tract
esions  should  not  be  overlooked  among  cardiology  patients,
specially  when  unexplained  anemia,  gastrointestinal  symp-
oms,  or  positive  FOBT  is  present,  and  GI  tract  screening
hould  be  performed  with  an  appropriate  timing.  Along  with
he  improvement  of  prognosis  of  cardiovascular  disease,  we
ay  have  to  pay  more  attention  to  the  treatment  and/or
anagement  of  comorbidities  that  may  have  a substantial
mpact  on  the  prognosis  and  health-related  quality  of  life,
uch  as  chronic  kidney  disease  [68]  psychological  status  [69],
nd  GI  malignancies.
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